Zedge에 대한 매도 수량은 투자자에게 Zedge의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Zedge (AMEX:ZDGE) 주식, 공매도 수량 보고

Zedge

Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

MITK

RICK

ZDGE

월요일(16일) 미국 주식 선물이 상승하고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다. 월요일 주목해야 할 주식: 젯지, 컴퍼스 미네랄스, 웨스턴 유니온, 미텍 및 RCI 호스피탈리티

월요일 주목해야 할 주식: 젯지, 컴퍼스 미네랄스, 웨스턴 유니온, 미텍 시스템즈 및 RCI 호스피탈리티

Zedge Inc

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Lam Research</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LRCX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Lam Research.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $120,250, and 10 are calls, for a total amount of $717,135.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $88.0 for Lam Research over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Lam Research's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Lam Research's substantial trades, within a strike price spectrum from $60.0 to $88.0 over the preceding 30 days.</p>
<h3>Lam Research Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734366624_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.45</td>
<td>$76.00</td>
<td>$222.5K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.45</td>
<td>$76.00</td>
<td>$167.7K</td>
<td>2.2K</td>
<td>502</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$16.8</td>
<td>$16.25</td>
<td>$16.8</td>
<td>$60.00</td>
<td>$84.0K</td>
<td>80</td>
<td>50</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.4</td>
<td>$13.3</td>
<td>$13.3</td>
<td>$88.00</td>
<td>$46.5K</td>
<td>964</td>
<td>43</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.73</td>
<td>$0.69</td>
<td>$0.7</td>
<td>$80.00</td>
<td>$45.0K</td>
<td>7.7K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lam Research</h3>
<p>Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.</p>
<p>After a thorough review of the options trading surrounding Lam Research, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Lam Research Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,214,827, with LRCX's price down by 0.0%, positioned at $76.26.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>Expert Opinions on Lam Research</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $82.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Lam Research, targeting a price of $78.<br />
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Market Perform rating on Lam Research with a target price of $85.<br />
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Lam Research, maintaining a target price of $83. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lam Research with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

LRCX

Check Out What Whales Are Doing With LRCX

<p>Financial giants have made a conspicuous bearish move on Adobe. Our analysis of options history for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) revealed 45 unusual trades.</p>
<p>Delving into the details, we found 31% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 36 were puts, with a value of $1,833,565, and 9 were calls, valued at $518,612.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $590.0 for Adobe over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Adobe options trades today is 708.37 with a total volume of 9,660.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Adobe's big money trades within a strike price range of $230.0 to $590.0 over the last 30 days.</p>
<h3>Adobe Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734366618_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.27</td>
<td>$1.23</td>
<td>$1.23</td>
<td>$450.00</td>
<td>$234.0K</td>
<td>2.7K</td>
<td>2.8K</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$266.95</td>
<td>$257.0</td>
<td>$262.98</td>
<td>$230.00</td>
<td>$210.3K</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$18.65</td>
<td>$16.35</td>
<td>$16.35</td>
<td>$480.00</td>
<td>$163.5K</td>
<td>2.1K</td>
<td>0</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$24.85</td>
<td>$24.1</td>
<td>$24.72</td>
<td>$350.00</td>
<td>$94.2K</td>
<td>175</td>
<td>42</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$78.55</td>
<td>$76.5</td>
<td>$76.75</td>
<td>$540.00</td>
<td>$92.1K</td>
<td>404</td>
<td>12</td>
</tr>
</tbody>
</table>
</p>
<h3>About Adobe</h3>
<p>Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).</p>
<h3>Present Market Standing of Adobe</h3>
<ul>
<li>Currently trading with a volume of 2,083,910, the ADBE's price is up by 0.68%, now at $468.84. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 87 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Adobe with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


ADBE

Adobe's Options: A Look at What the Big Money is Thinking

<p>Jim Carrey Returns To Acting, Saying, &#8216;I Bought A Lot Of Stuff,&#8217; Joining A Growing List Of Retired Actors Returning For Financial Reasons</p>
<p>For <a href="https://www.benzinga.com/real-estate/24/11/41982378/trumps-win-has-celebrities-saying-goodbye-america-see-where-theyre-going">Hollywood celebrities</a>, retirement does not necessarily mean ending one&#8217;s career. Jim Carrey recently disclosed that, as formerly one of the highest-paid actors in the world, the majority of his motivation for returning to acting was financial.&nbsp;</p>
<p>After Sonic the Hedgehog 2, the 62-year-old actor, who starred in classic films like The Truman Show and Liar Liar, declared in 2022 that he was retiring. At the time, he said he would only return for a special project that felt like it was written &#8220;in gold ink.&#8221;</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong> The percentage may shock you</strong></a>.</strong></li>
<li><strong>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"><strong> </strong><strong>here&#8217;s a breakdown on what&#8217;s behind this formula.</strong></a></strong></li>
</ul>
<p>Fast-forward less than two years, Carrey is back in Sonic the Hedgehog 3, playing Dr. Robotnik and his character&#8217;s grandfather. At the film&#8217;s London premiere, Carrey admitted, &#8220;I came back to this universe because I get to play a genius, which is a bit of a stretch. And it's just … I bought a lot of stuff and I need the money, frankly.&#8221;</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Jim Carrey explains his return to playing Dr. Robotnik in &quot;Sonic the Hedgehog 3&quot;: &quot;I bought a lot of stuff and I need the money, frankly.&quot; <a href="https://t.co/pIFJPuAyRM">pic.twitter.com/pIFJPuAyRM</a></p>
<p>&mdash; AP Entertainment (@APEntertainment) <a href="https://twitter.com/APEntertainment/status/1866579281045811233?ref_src=twsrc%5Etfw">December 10, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>While he joked about his financial situation, Carrey said the franchise's heartfelt story drew him back. With the first two Sonic movies grossing a combined $725 million globally, it's clear this isn't just a passion project – it's a smart paycheck.</p>
<p><strong>See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></p>
<p>Carrey isn't alone in returning to work to help balance the books. Hugh Grant, who plays an Oompa Loompa in the 2023 Wonka film, also admitted financial motivation. &#8220;I slightly hate [making films], but I have many children and need money,&#8221; Grant said at a press conference. The 63-year-old actor, who has five kids, shared that he found motion-capture work for the role &#8220;very uncomfortable&#8221; but took the part anyway.</p>
<p>Both Carrey and Grant were major stars at their peaks. During his heyday, Carrey commanded $20 million per movie, while Grant became a romantic-comedy legend. But big incomes don't always last forever. Carrey, for example, has been trying to sell his lavish Los Angeles mansion for nearly two years, cutting the price from $28.9 million to $19 million in September. He bought the property in 1994 for $3.8 million, but despite the discounts, it's clear he's looking for a significant profit.</p>
<p><strong>Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest TODAY for just $0.26/share with a $1000 minimum.</strong></a></strong></p>
<p>For Grant, who has once said he &#8220;pretty much hated any other film&#8221; he's ever been in, acting seems like a reluctant necessity to fund his large family. Similarly, despite his fortune, Carrey seems to be making choices to keep his financial footing steady.</p>
<p>These honest admissions show a growing trend among stars who find <a href="https://www.benzinga.com/money/retirement-planning-guide">retirement</a> less permanent than they thought. Whether it's a return for the love of storytelling, financial security or both, Carrey, Grant and others, remind us that even Hollywood royalty can face the reality of balancing the books – albeit with seven-figure paychecks.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a>.</strong></li>
<li><strong><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></strong></li>
</ul>


'I Bought A Lot Of Stuff,' Jim Carrey Admits, Joining Other Stars Returning To Acting Due To Money Woes After Retirement

<p>TD Cowen  analyst Max Rakhlenko   maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and raises the price target from $3450 to $3800.</p>


Price Target

Analyst Ratings

TD Cowen Maintains Buy on AutoZone, Raises Price Target to $3800

<p>Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) has outperformed the market over the past 5 years by 2.69% on an annualized basis producing an average annual return of 16.29%. Currently, Ciena has a market capitalization of $12.96 billion. </p>
<p><strong>Buying $100 In CIEN:</strong> If an investor had bought $100 of CIEN stock 5 years ago, it would be worth <strong>$217.10</strong> today based on a price of $90.16 for CIEN at the time of writing.</p>
<h3>Ciena's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734366607_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CIEN

$100 Invested In Ciena 5 Years Ago Would Be Worth This Much Today

<p>Lake Street  analyst Thomas Flaten   maintains Checkpoint Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) with a Buy and raises the price target from $4 to $7.</p>


CKPT

Lake Street Maintains Buy on Checkpoint Therapeutics, Raises Price Target to $7

<p><strong>Aehr Test Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) stock is trading higher on Monday after the company announced that it secured a $10 million order for artificial intelligence semiconductor testing <a href="https://www.benzinga.com//node/42505803">equipment</a>.</p>
<p><strong>The Details:</strong> The $10 million order includes multiple high-power FOX-XP wafer-level test and burn-in systems, as well as several sets of Aehr&#8217;s proprietary WaferPak Contactors.</p>
<p>This technology allows customers to perform production wafer-level burn-in for AI processors. It helps reduce costs and improve yields by identifying early life failures during production while the devices are still in wafer form, prior to assembly into modules or systems.</p>
<p>&#8220;This marks a technology and commercial breakthrough for Aehr as it significantly expands the market opportunities for our FOX-XP wafer level test and burn-in systems,&#8221; said <strong>Gayn Erickson</strong>, CEO of Aehr.</p>
<p>The first FOX-XP wafter system is scheduled to ship immediately, with the remaining systems and initial WaferPaks set to be delivered within 90 days.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/insights/news/24/12/42508964/heres-how-much-you-would-have-made-owning-applied-mat-stock-in-the-last-15-years">Here&#8217;s How Much You Would Have Made Owning Applied Mat Stock In The Last 15 Years</a></strong></p>
<p><strong>AEHR Price Action:</strong> At the time of publication, Aehr stock is trading 20.9% higher at $13.94 , according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: 5475664 from Pixabay.</em></p>


Movers

AEHR

What's Going On With Aehr Test Systems Shares Monday?

<p>JP Morgan  analyst Domingos Falavina   maintains PagSeguro Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGS#NYSE">PAGS</a>) with a Neutral and lowers the price target from $16 to $11.</p>


PAGS

JP Morgan Maintains Neutral on PagSeguro Digital, Lowers Price Target to $11

<p>TD Cowen  analyst Jonna Kim   initiates coverage on Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Hold rating and announces Price Target of $4.3.</p>


Initiation

WALD

TD Cowen Initiates Coverage On Waldencast with Hold Rating, Announces Price Target of $4.3

<p>Lake Street  analyst Ben Klieve   maintains Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Buy and raises the price target from $48 to $60.</p>


CHEF

Lake Street Maintains Buy on Chefs' Warehouse, Raises Price Target to $60

Macro Economic Events

Politics

Economics

General

President-Elect Trump Says Proposals Being Considered Include Federal Workers Who Don't Return To The Office Should Be Dismissed

<p><strong>Date Issued: December 16, 2024</strong></p>
<p>The U.S. Food and Drug Administration (FDA) is alerting patients, caregivers, and health care providers about the potential need for early device replacement <strong>of Boston Scientific Corporation (Boston Scientific) Accolade pacemaker devices</strong>, which includes the Accolade, Proponent, Essentio, and Altrua 2 Standard Life (SL) and Extended Life (EL) pacemakers, and the Visionist and Valitude cardiac resynchronization therapy pacemakers.</p>
<p>Boston Scientific announced a <a href="https://www.bostonscientific.com/content/dam/bostonscientific/quality/documents/Recent%20Product%20Advisories/2024_Dec_BSC_ACCOLADE_HighImpedance_PhysLtr_FINAL7_US.pdf">recall</a> for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode, which has limited functionality and has been associated with the pacemaker being unable to properly regulate the heart's rhythm and rate in some patients. A device that enters Safety Mode should be replaced. The increased risk of permanently entering Safety Mode in this subset of Accolade pacemaker devices is due to the battery underpowering the system because of a manufacturing issue. &nbsp;</p>
<p>While the recall by Boston Scientific identifies a subset of Accolade pacemaker devices with increased risk of entering Safety Mode, the FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices and identify additional mitigation strategies as needed.&nbsp;</p>
<p>The FDA is issuing this communication to raise awareness of the manufacturer's recall notice, the FDA's ongoing evaluation with the manufacturer of the issue, and the FDA's current recommendations.</p>
<h2><strong>Recommendations for Patients and Caregivers</strong></h2>
<ul>
<li>Continue to work with your health care provider to monitor your Accolade pacemaker device, either remotely or during your existing in-office follow-up schedule.&nbsp;
<ul>
<li>Discuss with your health care provider if you are a candidate for remote monitoring. Remote monitoring enables your provider to receive regular updates, including a Safety Mode alert, from your device.&nbsp;</li>
<li>If not a candidate for remote monitoring, discuss an in-office monitoring schedule with your health care provider to help ensure that your device is functioning properly.&nbsp;</li>
<li>If monitoring indicates that your device entered Safety Mode, discuss a plan with your health care provider for surgery to replace the pacemaker.&nbsp;</li>
</ul>
</li>
<li>Discuss your current pacing needs and potential risk of your device entering Safety Mode with your health care provider.
<ul>
<li>If you are determined to be at high risk of harm &nbsp;if your device entered Safety Mode based on your pacing needs, your health care provider may contact you about replacement of your device.</li>
</ul>
</li>
<li>Consult with your health care provider if you have new or worsening symptoms such as lightheadedness or loss of consciousness, or questions about your device potentially entering Safety Mode.&nbsp;</li>
<li><a href="http://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety#reporting">Report any problems</a> with your Accolade pacemaker device to the FDA.</li>
</ul>
<h2><strong>Recommendations for Health Care Providers</strong></h2>
<ul>
<li>Review the <a href="https://www.bostonscientific.com/content/dam/bostonscientific/quality/documents/Recent%20Product%20Advisories/2024_Dec_BSC_ACCOLADE_HighImpedance_PhysLtr_FINAL7_US.pdf">recall notice</a> from Boston Scientific for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode due to the battery underpowering the system because of a manufacturing issue with the battery cathode. The recall notice includes the following important information:
<ul>
<li>Description of the battery problem and clinical impact of Safety Mode,</li>
<li>Recommended actions for individual patient evaluation, device replacement, and follow-up intervals, and</li>
<li>Model numbers and Unique Device Identifier (UDI) information.&nbsp;</li>
</ul>
</li>
<li>Be aware that the FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices.
<ul>
<li>Consider the potential need for early device replacement and a patient's specific reliance on their pacemaker when making treatment recommendations.</li>
<li>Discuss the benefit and risks of all available treatment options with your patients.&nbsp;</li>
<li>Remain alert for further updates and recommendations from the FDA and the manufacturer.</li>
<li>While the FDA's evaluation is ongoing, health care providers should:
<ul>
<li>Monitor patients with Accolade pacemaker devices through remote or in-office visits for red box alerts indicating that a patient's device is in Safety Mode, or symptoms indicating device performance issues, such as lightheadedness or loss of consciousness. General prophylactic device replacement is not recommended.&nbsp;</li>
<li>If monitoring indicates that the device has entered Safety Mode, schedule surgery for a replacement pacemaker. Timely replacement is recommended to avoid risks associated with time spent in Safety Mode.</li>
</ul>
</li>
</ul>
</li>
<li><a href="http://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety#reporting">Report any problems</a> your patients experience with Accolade pacemaker devices to the FDA.</li>
</ul>
<h2><strong>Device Description</strong></h2>
<p>The Accolade devices are a family of pacemakers and cardiac resynchronization therapy pacemakers that are implanted to treat abnormal heartbeat (arrhythmia) and moderate to severe heart failure.</p>
<h2><strong>Potential Need for Early Device Replacement of Accolade Pacemaker Devices</strong></h2>
<p>The FDA is aware of a manufacturing issue with the cathode of some Accolade pacemaker device batteries that may lead to underpowering the device system and may cause the pacemakers to permanently enter Safety Mode, which requires pacemaker replacement.</p>
<p>Pacemakers that enter Safety Mode require replacement because Safety Mode offers limited functioning of the pacemaker and has been associated with the pacemaker being unable to properly regulate the heart's rhythm and rate in some patients. Safety Mode can only be identified through office visits or through remote monitoring using the Boston Scientific Latitude Communicator system.</p>
<p>The manufacturer plans to implement updated manufacturing work instructions for the process used to make the cathodes for Accolade product batteries. In addition, the manufacturer is developing a software update to detect battery health in all Accolade pacemaker devices.</p>
<h2><strong>FDA Actions</strong></h2>
<p>The FDA will continue working with Boston Scientific to help ensure that patients, caregivers, and providers are aware of the issue, evaluate information to better understand the issue, and to identify additional mitigation strategies as needed. &nbsp; &nbsp;</p>
<p>The FDA will continue to monitor information about device performance including medical device reports.</p>
<p>The FDA will keep the public informed as new information becomes available.</p>


FDA Alerting About Potential Need For Early Device Replacement Of Boston Scientific Accolade Pacemaker Devices; Boston Scientific Announced Recall For Subset Of Accolade Pacemaker Devices With Increased Risk To Permanently Enter Safety Mode

<p>JP Morgan  analyst Yuri Fernandes   maintains StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) with a Overweight and lowers the price target from $21 to $15.</p>


STNE

JP Morgan Maintains Overweight on StoneCo, Lowers Price Target to $15

<p>Despite <strong>Cardano's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) 4% decline over the past week, crypto traders and community developments paint an optimistic picture for the <a href="https://www.benzinga.com/money/cardano-price-prediction">altcoin&#8217;s near-term future</a>.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>24-Hour Trend</strong></td>
<td><strong>7-Day Trend</strong></td>
</tr>
<tr>
<td><strong>Cardano</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>&nbsp;$1.07</td>
<td>$37.5 billion</td>
<td>-1.8%&nbsp;</td>
<td>&nbsp;-4.2%</td>
</tr>
<tr>
<td><strong>TRON</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>)</td>
<td>&nbsp;$0.282</td>
<td>$24.3 billion</td>
<td>-0.95%</td>
<td>&nbsp;-3.2%</td>
</tr>
<tr>
<td><strong>Avalanche</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>)</td>
<td>&nbsp;$49</td>
<td>$20 billion</td>
<td>-2.9%&nbsp;</td>
<td>+0/08%&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>Crypto trader Cantonese Cat noted that ADA's weekly close <a href="https://x.com/cantonmeow/status/1868458730834264111">signals</a> potential for significant upward momentum.</p>
<p>Similarly, Rose Premium Signals highlighted a symmetrical triangle pattern on Cardano's daily chart, which suggests a bullish breakout may be imminent. </p>
<p>With the price hovering near a key support zone at $0.9168, this could present a prime buying opportunity.</p>
<p>Projected breakout targets include: $1.4594, $1.7574 and $2.0387. The trader advises placing a stop loss below $0.89 to mitigate risks.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Technical Analysis for <a href="https://twitter.com/hashtag/ADA?src=hash&amp;ref_src=twsrc%5Etfw">#ADA</a>/USDT:<a href="https://twitter.com/search?q=%24ADA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ADA</a> The daily chart indicates the formation of a symmetrical triangle, suggesting a potential breakout in the bullish direction. The current price at $1.059 is near the lower support zone. Key support lies at $0.9168, presenting an ideal buying… <a href="https://t.co/VSnqwO2a0F">pic.twitter.com/VSnqwO2a0F</a></p>
<p>&mdash; Rose Premium Signals &#x1f339; (@VipRoseTr) <a href="https://twitter.com/VipRoseTr/status/1867997609799139608?ref_src=twsrc%5Etfw">December 14, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Statistics: </strong>IntoTheBlock data shows Cardano's large transaction volume and daily active addresses increasing by 0.4% and 3.7%, respectively. Large transaction volume are up from 1,201 to 1,480 in a single day.</p>
<p>With Cardano up 38% month-over-month, around 66% holders are in profit and 9% at breakeven.</p>
<p><strong>Community News: </strong>Cardano's co-founder, <strong>Charles Hoskinson</strong>, expressed his vision for 2025, foreseeing a flourishing ecosystem with numerous projects and developers contributing to the blockchain.</p>
<p>Hoskinson emphasized the importance of embracing innovative features like Hydra, Partnerchains, and Leios, which will enhance Cardano's usability and scalability. He views these advancements as critical for positioning Cardano as the backbone of global economic, political and social systems.</p>
<p>"This vision is ambitious yet achievable through collective effort and unwavering commitment," <a href="https://x.com/IOHK_Charles/status/1867968599958438060">said</a> Hoskinson on <strong>X</strong> on Saturday.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/education/24/11/42098422/heres-how-much-100-invested-in-cardano-today-could-be-worth-if-ada-hits-new-all-time-highs">Here&#8217;s How Much $100 Invested In Cardano Today Could Be Worth If ADA Hits New All-Time Highs</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$AVAX

$TRX

Cardano Down 4% In A Week: What Is Going On With ADA?

<p>Shares of <strong>Teradyne Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) </strong><a href="https://www.benzinga.com/quote/ter">climbed in early trading on Monday</a>.</p>
<p>Growth of the semiconductor test total addressable market is likely to accelerate further in 2025, according to JPMorgan.</p>
<p><a href="https://www.benzinga.com/24/11/42145521/netapp-analysts-raise-their-forecasts-after-strong-earnings">Analyst Samik Chatterjee</a> upgraded the rating for Teradyne from Neutral to Overweight, while raising the price target from $145 to $158.</p>
<p><strong>The Teradyne </strong><strong>Thesis: </strong>The semiconductor test TAM that is relevant to the company is likely to reach $6.4 billion in 2025 and accelerate further to $7.6 billion in 2026, Chatterjee said in the upgrade note.</p>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.</strong></p>
<p>Teradyne is likely to gain a higher share in the verification IP ASIC market and increase its share of the high bandwidth memory market, which would drive an acceleration in the company's revenue growth to low-20% in 2025 and high-20% in 2026, the analyst stated.</p>
<p>"Our updated outlook for the TAM leads us to forecast Teradyne revenues tracking to $4.4 bn in 2026, towards the high-end of its earlier outlined target for a range of $3.9-$4.6 bn of revenue, and we now forecast EPS of $6.75 in 2026 towards the higher-end of the outlined range of $5.50-$7.50, he further wrote.</p>
<p><strong>TER Price Action:</strong> Shares of Teradyne were up 4.2% to $128.51 at the time of publication Monday.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42443202/2025-investment-themes-ai-energy-defense-redefine-us-markets">2025 Investment Themes: AI, Energy, Defense Redefine US Markets</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Upgrades

Teradyne Rises After Analyst's Upbeat Forecast For 2025 Growth

WIIM

TSLA

Tesla shares are trading higher after Wedbush maintained an Outperform rating on the stock and raised its price target from $400 to $515.

<p>Citigroup  analyst Patrick Cunningham   maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Buy and lowers the price target from $48 to $45.</p>


Citigroup Maintains Buy on Olin, Lowers Price Target to $45

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Cleveland-Cliffs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with CLF, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for Cleveland-Cliffs.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 27% bullish and 45%, bearish.</p>
<p>Out of all of the options we uncovered, 10 are puts, for a total amount of $1,685,535, and there was 1 call, for a total amount of $80,760.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $20.0 for Cleveland-Cliffs during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Cleveland-Cliffs's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cleveland-Cliffs's whale activity within a strike price range from $10.0 to $20.0 in the last 30 days. </p>
<h3>Cleveland-Cliffs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734365735_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$10.25</td>
<td>$10.0</td>
<td>$10.05</td>
<td>$20.00</td>
<td>$301.5K</td>
<td>3.2K</td>
<td>300</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$10.05</td>
<td>$9.95</td>
<td>$10.0</td>
<td>$20.00</td>
<td>$300.0K</td>
<td>3.2K</td>
<td>600</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.95</td>
<td>$9.9</td>
<td>$9.95</td>
<td>$20.00</td>
<td>$298.5K</td>
<td>3.2K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.0</td>
<td>$9.85</td>
<td>$9.9</td>
<td>$20.00</td>
<td>$297.0K</td>
<td>3.2K</td>
<td>900</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$9.9</td>
<td>$9.8</td>
<td>$9.85</td>
<td>$20.00</td>
<td>$295.5K</td>
<td>3.2K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cleveland-Cliffs</h3>
<p>Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.</p>
<h3>Where Is Cleveland-Cliffs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 5,212,598, the CLF's price is down by -0.88%, now at $10.12. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About Cleveland-Cliffs</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $16.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Buy, setting a price target of $16. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Cleveland-Cliffs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Cleveland-Cliffs Options Trading: A Deep Dive into Market Sentiment

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>CrowdStrike Holdings</strong>.</p>
<p>Looking at options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) we detected 33 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 30% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $502,610 and 27, calls, for a total amount of $1,580,977.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $500.0 for CrowdStrike Holdings, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for CrowdStrike Holdings options trades today is 1340.92 with a total volume of 13,996.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for CrowdStrike Holdings's big money trades within a strike price range of $300.0 to $500.0 over the last 30 days.</p>
<h3>CrowdStrike Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734365731_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$3.05</td>
<td>$2.79</td>
<td>$2.96</td>
<td>$330.00</td>
<td>$309.3K</td>
<td>20</td>
<td>1.0K</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$23.65</td>
<td>$23.2</td>
<td>$23.65</td>
<td>$380.00</td>
<td>$236.5K</td>
<td>896</td>
<td>101</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$19.95</td>
<td>$19.3</td>
<td>$19.7</td>
<td>$360.00</td>
<td>$139.8K</td>
<td>1.9K</td>
<td>248</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$117.8</td>
<td>$117.05</td>
<td>$117.8</td>
<td>$300.00</td>
<td>$117.8K</td>
<td>1.3K</td>
<td>11</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.15</td>
<td>$1.91</td>
<td>$2.1</td>
<td>$385.00</td>
<td>$93.3K</td>
<td>446</td>
<td>706</td>
</tr>
</tbody>
</table>
</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<p>After a thorough review of the options trading surrounding CrowdStrike Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of CrowdStrike Holdings</h3>
<ul>
<li>Trading volume stands at 1,297,276, with CRWD's price up by 2.62%, positioned at $377.68.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 78 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CrowdStrike Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CRWD

Check Out What Whales Are Doing With CRWD

<p>Deep-pocketed investors have adopted a bullish approach towards Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CRM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Salesforce. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 51% leaning bullish and 28% bearish. Among these notable options, 2 are puts, totaling $93,470, and 33 are calls, amounting to $2,666,794.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $400.0 for Salesforce during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Salesforce options trades today is 2089.22 with a total volume of 2,225.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Salesforce's big money trades within a strike price range of $230.0 to $400.0 over the last 30 days.</p>
<h3>Salesforce Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734365726_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$58.25</td>
<td>$57.9</td>
<td>$57.95</td>
<td>$300.00</td>
<td>$405.1K</td>
<td>6.0K</td>
<td align="right">75</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.95</td>
<td>$11.4</td>
<td>$11.45</td>
<td>$400.00</td>
<td>$241.6K</td>
<td>2.3K</td>
<td align="right">218</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$36.15</td>
<td>$34.6</td>
<td>$34.6</td>
<td>$360.00</td>
<td>$173.0K</td>
<td>1.2K</td>
<td align="right">100</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$36.3</td>
<td>$34.6</td>
<td>$34.6</td>
<td>$360.00</td>
<td>$173.0K</td>
<td>1.2K</td>
<td align="right">50</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$115.4</td>
<td>$114.75</td>
<td>$115.4</td>
<td>$240.00</td>
<td>$150.0K</td>
<td>1.6K</td>
<td align="right">24</td>
</tr>
</tbody>
</table>
</p>
<h3>About Salesforce</h3>
<p>Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.</p>
<p>Having examined the options trading patterns of Salesforce, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Salesforce Standing Right Now?</h3>
<ul>
<li>With a volume of 1,682,630, the price of CRM is up 0.05% at $354.49. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 72 days.</li>
</ul>
<h3>What The Experts Say On Salesforce</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $387.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $450.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Salesforce, targeting a price of $395.<br />
&#x2A; In a cautious move, an analyst from Oppenheimer downgraded its rating to Outperform, setting a price target of $385.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Salesforce with a target price of $368.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Salesforce, which currently sits at a price target of $340. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Salesforce, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Decoding Salesforce's Options Activity: What's the Big Picture?

Zedge Inc ( ($ZDGE) ) has realeased its Q4 earnings. Here is a breakdown of the information Zedge Inc presented to its investors. Zedge, Inc. is a ...

Zedge Reports Strong Revenue Growth Amid Challenges

Zedge Inc (ZDGE) has disclosed a new risk, in the Trade Secrets category. Zedge Inc faces significant risks in safeguarding its intellectual proper...

Zedge Inc's Global Intellectual Property Challenges: Navigating Risks and Safeguarding Competitive Edge

Zedge (ZDGE – Research Report), the Communication Services sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Klee fro...

Zedge's Growth Potential Highlighted Amidst Revenue Miss: Buy Rating Affirmed

GameSquare made a company-changing acquisition that has already paid for itself multiple times over through sales of parts, $18M in cost-cutting, and a flurry of deals. It's speeding towards being cash flow positive. The shares are cheap.

A Game Changer For GameSquare

Zedge Q1 2025 Earnings Preview

Zedge Non-GAAP EPS of $0.00 misses by $0.03, revenue of $7.2M misses by $0.08M

"We anticipate significant improvements in our second quarter driven by traditional holiday seasonal strength and the resolution of key challenges ...

Zedge CEO anticipates 'significant improvements' in Q2

Reports Q1 revenue $7.2M vs. $7.1M last year. Jonathan Reich, Zedge's (ZDGE) CEO, commented: "We are encouraged by the underlying trends in our bus...

Zedge reports Q1 EPS 0c vs. 4c last year

Zedge Non-GAAP EPS of $0.00, revenue of $7.2M

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Viridian Therapeutics&nbsp;(VRDN) up 23% after reporting...

Morning Movers: Viridian and Edgewise jump following successful trials

CPRI

EGLXF

EWTX

GAME

HEAR

MCHP

MSFT

NSANY

SMCI

SVNDY

VRDN

Events

Press Releases

Zedge to Participate in the Maxim Group 2024 Gaming, Media & Entertainment Virtual Conference

Zedge Announces New $5 Million Share Repurchase Program

Zedge Unveils Significant Enhancements to its Gen AI Creation Tool for iOS

Zedge To Report Fourth Quarter And End Of Year Fiscal 2024 Results

Zedge's GuruShots Photography Game Introduces Exciting New Features: Onboarding, Missions and Enhanced Game Economy

Zedge Announces Fourth Quarter and Full Year Fiscal 2024 Results

Zedge Marketplace Introduces Major Website Updates

Emojipedia Launches Free AI-Powered Emoji Creator

Zedge To Report First Fiscal Quarter 2025 Results

Zedge Announces First Quarter Fiscal 2025 Results

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Comments

Zedge

매도 수량

Zedge (AMEX:ZDGE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌